Should the ovaries be removed or retained at the time of hysterectomy for benign disease?

Human Reproduction Update

Volumn 16, Issue 2, 2009, Pages

  Hickey, M ^a   Ambekar, M ^a   Hammond, I ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Bilateral salpingoophorectomy; Endometriosis; Ovarian cancer; Premenstrual syndrome; Surgical menopause

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; PROGESTERONE; TESTOSTERONE; TIBOLONE;

ARTERY CALCIFICATION; ATHEROSCLEROSIS; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITIVE DEFECT; CORONARY ARTERY DISEASE; DRUG MEGADOSE; ENDOMETRIOID CARCINOMA; ENDOMETRIOSIS; FRAGILITY FRACTURE; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; ISCHEMIC HEART DISEASE; MEMORY DISORDER; MORTALITY; OSTEOPOROSIS; OVARIAN PRESERVATION; OVARIECTOMY; OVARY CANCER; OVARY CYST; PELVIS PAIN SYNDROME; POSTMENOPAUSE; PREMENOPAUSE; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; REOPERATION; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SALPINGOOOPHORECTOMY; SEXUAL FUNCTION; SURGICAL RISK; UTERINE TUBE LIGATION; VASOMOTOR DISORDER;

EID: 77649266406     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmp037     Document Type: Review

References (86)

1. ACN&NBCC. The Australian Cancer Network and National Breast Cancer Centre Clinical practice guidelines for the management of women with epithelial ovarian cancer. Canberra, 2004.
2. AIHW. Australian Institute of Health and Welfare Australian hospital statistics 2002-03. Canberra, 2003.
3. Allison MA, Manson JE, Langer RD, Carr JJ, Rossouw JE, Pettinger MB, Phillips L, Cochrane BB, Eaton CB, Greenland P et al. Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study. Menopause 2008;15:639-647.
4. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004; 291:1701-1712.
5. Antoniucci DM, Sellmeyer DE, Cauley JA, Ensrud KE, Schneider JL, Vesco KK, Cummings SR, Melton L Jr, Group SoOFR. Postmenopausal bilateral oophorectomy is not associated with increased fracture risk in older women. J Bone Miner Res 2005; 20:741-747.
6. Areia A, Sousa V, Frutuoso C, Dias I, Martins MI, de Oliveira CF. Endometrioid adenocarcinoma arising in endometriosis foci six years after estrogen replacement therapy: a case report. Eur J Gynaecol Oncol 2004;25:255-256.
7. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-279.
8. Aziz A, Brännström M, Bergquist C, Silfverstolpe G. Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil Steril 2005;83:1021-1028.
9. Bachmann GA. Vasomotor flushes in menopausal women. Am J Obstet Gynecol 1999;180:S312-S316.
10. Bourdrez P, Bongers MY, Mol BW. Treatment of dysfunctional uterine bleeding: patient preferences for endometrial ablation, a levonorgestrel-releasing intrauterine device, or hysterectomy. Fertil Steril 2004;82:160-166.
11. Burger H. The menopausal transition-endocrinology. J Sex Med 2008; 5:2266-2273.
12. Callahan MJ, Crum CP, Medeiros F, Kindelberger DW, Elvin JA, Garber JE, Feltmate CM, Berkowitz RS, Muto MG. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol 2007;25:3985-3990.
13. Celik H, Gurates B, Yavuz A, Nurkalem C, Hanay F, Kavak B. The effect of hysterectomy and bilaterally salpingo-oophorectomy on sexual function in post-menopausal women. Maturitas 2008;61:358-363.
14. Chiaffarino F, Parazzini F, Decarli A, Franceschi S, Talamini R, Montella M, La Vecchia C. Hysterectomy with or without unilateral oophorectomy and risk of ovarian cancer. Gynecol Oncol 2005;97:318-322.
15. Cronje WH, Vashisht A, Studd JW. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum Reprod 2004; 19:2152-2155.
16. Davies A, O'Connor H, Magos AL. A prospective study to evaluate oophorectomy at the time of vaginal hysterectomy. Br J Obstet Gynaecol 1996;103:915-920.
17. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA 2005;294:91-96.
18. Davis S, Papalia MA, Norman RJ, O'Neill S, Redelman M, Williamson M, Stuckey BG, Wlodarczyk J, Gard'ner K, Humberstone A. Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial. Ann Intern Med 2008;148:569-577.
19. Dennerstein L, Dudley E, Burger H. Are changes in sexual functioning during midlife due to aging or menopause? Fertil Steril 2001;76:456-460.
20. Di Giulio G, Reissing ED. Premenstrual dysphoric disorder: prevalence, diagnostic considerations, and controversies. J Psychosom Obstet Gynaecol 2006;27:201-210.
21. Dorjgochoo T, Shu XO, Li HL, Qian HZ, Yang G, Cai H, Gao YT, Zheng W. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer 2008;124:2442-2449.
22. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005; 23:7491-7496.
23. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, Kim-Sing C, Neuhausen SL, Gilbert L, Ghadirian P et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst 2008;100:1361-1367.
24. Evans GR, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous M et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet 2008 [Epub ahead of print].
25. Farquhar CM, Harvey SA, Yu Y, Sadler L, Stewart AW. A prospective study of 3 years of outcomes after hysterectomy with and without oophorectomy. Am J Obstet Gynecol 2006;194:711-717.
26. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Friedman E, Foulkes WD et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006;296:185-192.
27. Francucci CM, Romagni P, Camilletti A, Fiscaletti P, Amoroso L, Cenci G, Morbidelli C, Boscaro M. Effect of natural early menopause on bone mineral density. Maturitas 2008;59:323-328.
28. Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause 2007;14:567-571.
29. Garry R, Fountain J, Mason S, Hawe J, Napp V, Abbott J, Clayton R, Phillips G, Whittaker M, Lilford R et al. The eVALuate study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal hysterectomy. BMJ 2004;328:129.
30. Green A, Purdie D, Bain C, Siskind V, Russell P, Quinn M, Ward B. Tubal sterilisation, hysterectomy and decreased risk of ovarian cancer. Survey of Women's Health Study Group. Int J Cancer 1997;71:948-951.
31. Halperin R, Mordechai E, Zehavi S, Schneider D. Pathological characteristics of ovarian cancer occurring after hysterectomy. Eur J Gynaecol Oncol 2004;25:308-310.
32. Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Miller VM, Naftolin F, Santoro N. KEEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005;8:1-2.
33. Henderson VW, Sherwin BB. Surgical versus natural menopause: cognitive issues. Menopause 2007;14:572-579.
34. Hickey M, Davis SR, Sturdee DW. Treatment of menopausal symptoms: what shall we do now? Lancet 2005;366:409-421.
35. Hickey M, Saunders CM, Partridge A, Santoro N, Joffe H, Stearns V. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 2008;19:1669-1680.
36. Holmberg L, Anderson H, for Committees HSDM. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped. Lancet 2004;363:453-455.
37. Holub Z, Jandourek M, Jabor A, Kliment L, Wágnerová M. Does hysterectomy without salpingo-oophorectomy influence the reoperation rate for adnexal pathology? A retrospective study. Clin Exp Obstet Gynecol 2000;27:109-112.
38. Howard BV, Kuller L, Langer R, Manson JE, Allen C, Assaf A, Cochrane BB, Larson JC, Lasser N, Rainford M et al. Risk of cardiovascular disease by hysterectomy status, with and without oophorectomy: the Women's Health Initiative Observational Study. Circulation 2005;111:1462-1470.
39. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-452.
40. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber J, Isaacs C, Evans DG, Lynch H, Eeles RA et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1-and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008;26:1331-1337.
41. Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009;10:135-146.
42. Kotsopoulos J, Lubinski J, Neuhausen SL, Lynch HT, Rosen B, Ainsworth P, Moller P, Ghadirian P, Isaacs C, Karlan B et al. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 2006;100:83-88.
43. Kotz K, Alexander JL, Dennerstein L. Estrogen and androgen hormone therapy and well-being in surgically postmenopausal women. J Womens Health (Larchmt) 2006;15:898-908.
44. Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman JA, Robson ME, Offit K, Barakat RR et al. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:4222-4227.
45. Lobo RA. Surgical menopause and cardiovascular risks. Menopause 2007; 14:562-566.
46. Løkkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of hormone therapy. Maturitas 2006;53:226-233.
47. MacDonald SR, Klock SCK, Milad MP. Long-term outcome of nonconservative surgery (hysterectomy) for endometriosis-associated pain in women <30 years old. Am J Obstet Gynecol 1999; 180:1360-1363.
48. MacLennan A, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;18: CD002978.
49. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006; 24:3576-3582.
50. Melton L Jr, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 2003;18:900-905.
51. Michelsen TM, Pripp AH, Tonstad S, Tropé CG, Dørum A. Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer 2009;45:82-89.
52. Namnoum AB, Hickman TN, Goodman SB, Gehlbach DL, Rock JA. Incidence of symptom recurrence after hysterectomy for endometriosis. Fertil Steril 1995;64:898-902.
53. Negri E, Pelucchi C, Franceschi S, Montella M, Conti E, Dal Maso L, Parazzini F, Tavani A, Carbone A, La Vecchia C. Family history of cancer and risk of ovarian cancer. Eur J Cancer 2003;39:505-510.
54. Orozco LJ, Salazar A, Clarke J, Tristan M. Hysterectomy versus hysterectomy plus oophorectomy for premenopausal women. Cochrane Database Syst Rev 2008;16:CD005638.
55. Parker WH, Shoupe D, Broder MS, Liu Z, Farquhar C, Berek JS. Elective oophorectomy in the gynecological patient: when is it desirable? Curr Opin Obstet Gynecol 2007;19:350-354.
56. Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol 2009;113:1027-1037.
57. Pell I, Dowie J, Clarke A, Kennedy A, Bhavnani V. Development and preliminary evaluation of a clinical guidance programme for the decision about prophylactic oophorectomy in women undergoing a hysterectomy. Qual Saf Health Care 2002;11:32-38.
58. Piver MS. Prophylactic oophorectomy: reducing the U.S. death rate from epithelial ovarian cancer. A continuing debate. Oncologist 1996; 1:326-330.
59. Plöckinger B, Kölbl H. Development of ovarian pathology after hysterectomy without oophorectomy. J Am Coll Surg 1994; 178:581-585.
60. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008; 23:1507-1513.
61. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005; 23:7804-7810.
62. Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-ooprhorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009; 101:80-87.
63. Rhodes JC, Kjerulff KH, Langenberg PW, Guzinski GM. Hysterectomy and sexual functioning. JAMA 1999;282:1934-1941.
64. Rinaudo P, Strauss JF III. Endocrine function of the postmenopausal ovary. Endocrinol Metab Clin North Am 2004;33:661-674.
65. Rivera CM, Grossardt BR, Rhodes DJ, Brown RDJ, Roger VL, Melton LJ III, Rocca WA. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009;16:15-23.
66. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ III. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-1083.
67. Rocca WA, Shuster LT, Grossardt BR, Maraganore DM, Gostout BS, Geda YE, Melton LJ III. Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Womens Health (Lond Engl) 2009;5:39-48.
68. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
69. Schmeler KM, Lu KH. Gynecologic cancers associated with Lynch syndrome/HNPCC. Clin Transl Oncol 2008;10:313-317.
70. Schwartz MD, Valdimarsdottir HB, DeMarco TA, Peshkin BN, Lawrence W, Rispoli J, Brown K, Isaacs C, O'Neill S, Shelby R et al. Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol 2009;28:11-19.
71. Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery. Obstet Gynecol 2008;111:1285-1292.
72. Shifren JL, Avis NE. Surgical menopause: effects on psychological well-being and sexuality. Menopause 2007;14:586-591.
73. Shoupe D, Parker WH, Broder MS, Liu Z, Farquhar C, Berek JS. Elective oophorectomy for benign gynecological disorders. Menopause 2007; 14:580-585.
74. Shwayder JM. Pelvic pain, adnexal masses, and ultrasound. Semin Reprod Med 2008;26:252-265.
75. Soliman NF, Hillard TC. Hormone replacement therapy in women with past history of endometriosis. Climacteric 2006;9:325-335.
76. Stratton JF, Gayther SA, Russell P, Dearden J, Gore M, Blake P, Easton D, Ponder BA. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 1997;336:1125-1130.
77. Sundar SS, Gornall RJ, Kerr-Wilson R, Swingler GR, Kinder RB, McCarthy K. A case report of recurrent endometriosis following Tibolone hormone replacement therapy. J Obstet Gynaecol 2007; 27:433-434.
78. Teplin V, Vittinghoff E, Lin F, Learman LA, Richter HE, Kuppermann M. Oophorectomy in premenopausal women: health-related quality of life and sexual functioning. Obstet Gynecol Surv 2007;109:347-354.
79. van Dongen H, van de Merwe AG, de Kroon CD, Jansen FW. The impact of alternative treatment for abnormal uterine bleeding on hysterectomy rates in a tertiary referral center. J Minim Invasive Gynecol 2009; 16:47-51.
80. Vearncombe KJ, Pachana NA. Is cognitive functioning detrimentally affected after early, induced menopause? Menopause 2009;16:188-198.
81. Vercellini P, Barbara G, Abbiati A, Somigliana E, Vigano' P, Fedele L. Repetitive surgery for recurrent symptomatic endometriosis: What to do? Eur J Obstet Gynecol Reprod Biol 2009;146:15-21.
82. von Schoultz E, Rutqvist LE. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst 2005; 97:533-535.
83. Weir E, Mustard C, Cohen M, Kung R. Endometriosis: what is the risk of hospital admission, readmission, and major surgical intervention? J Minim Invasive Gynecol 2005;12:486-493.
84. Wierman ME, Basson R, Davis SR, Khosla S, Miller KK, Rosner W, Santoro N. Androgen therapy in women: an Endocrine Society Clinical Practice guideline. J Clin Endocrinol Metab 2006; 91:3697-3710.
85. Wu JM, Wechter ME, Geller EJ, Nguyen TV, Visco AG. Hysterectomy rates in the United States, 2003. Obstet Gynecol 2007; 110:1091-1095.
86. Zalel Y, Lurie S, Beyth Y, Goldberger S, Tepper R. Is it necessary to perform a prophylactic oophorectomy during hysterectomy? Eur J Obstet Gynecol Reprod Biol 1997;73:67-70.